Cardiol Therapeutics (CRDL) EBITDA (2020 - 2026)

Cardiol Therapeutics' EBITDA history runs 6 years deep, the most recent figure standing at -$7.1 million for Q1 2026.

• Quarterly EBITDA fell 20.49% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.9 million (up 10.56% YoY) and the FY2025 annual result came in at -$24.6 million, up 14.65% from the prior year.
• EBITDA was -$7.1 million for Q1 2026 at Cardiol Therapeutics, down from -$5.9 million in the prior quarter.
• Across five years, EBITDA topped out at -$5.9 million in Q1 2025 and bottomed at -$10.1 million in Q3 2022.
• A 4-year average of -$7.3 million and a median of -$7.1 million in 2026 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 35.52% in 2022, while the deepest fall reached 39.3% in 2022.
• Cardiol Therapeutics' EBITDA stood at -$6.7 million in 2022, then climbed by 6.9% to -$6.2 million in 2024, then rose by 5.83% to -$5.9 million in 2025, then decreased by 20.49% to -$7.1 million in 2026.
• Business Quant data shows CRDL's EBITDA at -$7.1 million in Q1 2026, -$5.9 million in Q1 2025, and -$6.2 million in Q1 2024.